Table 1. Main characteristics of the included studies.

First author,	Country	Patients with	GP73						AFP						GP73 + AFP
year (ref.)		HCC/Controls	TP	FP	FN	TN	Cut-off	Method	TP	FP	FN	TN	Cut-off	Method	TP	FP	FN	TN
Jia, 2014 [18]	China	102/179	79	20	23	159	150 ng/mL	ELISA	53	39	49	140	400 ng/mL	Immunoassay	-	-	-	-
Wang, 2013 [19]	China	84/173	62	32	22	141	8.5 RU	Immunoblotting	66	26	22	147	NK	Immunoassay	67	26	17	147
Hou, 2013 [20]	China	79/105	58	21	21	84	78.1 ng/L	Immunoblotting	44	14	35	91	47.8 ng/mL	Immunoassay	70	32	9	73
Shi, 2011 [9]	China	73/107	50	7	23	100	100 μg/L	ELISA	21	1	52	106	400 μg/L	ELISA	54	8	19	99
Morota, 2011 [21]	Japan	70/159	62	61	8	98	94.7 μg/L	ELISA	44	13	26	146	15.3 μg/L	ELISA	-	-	-	-
Tian, 2010 [22]	China	153/95	115	46	38	49	113.89 μg/L	ELISA	145	50	8	45	13.6 μg/L	ELISA	-	-	-	-
Ozkan, 2010 [23]	Turkey	75/55	62	50	13	5	0.078 mg/mL	ELISA	51	3	24	52	13 ng/mL	ELISA	-	-	-	-
Mao, 2010 [24]	China/USA	789/3428	589	89	200	3339	8.5 RU	Immunoblotting	459	504	330	2924	35 ng/mL	Immunoassay	704	507	85	2921
Hu, 2009 [25]	China	31/93	24	15	7	78	7.4 RU	Western blotting	15	3	16	90	36 μg/L	ELISA	-	-	-	-
Wang, 2009 [26]	USA	164/113	156	64	8	49	NK	Immunoblotting	156	79	8	34	NK	ELISA	-	-	-	-
Marrero, 2005 [27]	USA	144/152	99	21	45	131	10 RU	Immunoblotting	43	6	101	146	99 ng/mL	ELISA	-	-	-	-

TP: true positive; FP: false positive; FN: false negative; TN: true negative; -: no data for this category; RU: relative unit; NK: not known; ref.: reference number; HCC: hepatocellular carcinoma.